Pfizer Inc.
PFE
Rang in Aktien
#112
Pfizer Inc. is a global biopharmaceutical leader engaged in the research,... Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Aktienkurs
$30.15
Marktkapitalisierung
$171.82B
Veränderung (1 Tag)
2.31%
Veränderung (1 Jahr)
22.09%
Land
US
Handel Pfizer Inc. (PFE)
Kategorie
Healthcare
Umsatz von Pfizer Inc. (PFE)
Umsatz im Jun 2026 TTM: $63.70B
Laut den aktuellen Finanzberichten von Pfizer Inc. beträgt der derzeitige Umsatz des Unternehmens (TTM) $63.70B. Im Jahr 2024 erzielte das Unternehmen einen Umsatz von $63.63B eine Steigerung gegenüber dem Umsatz im Jahr 2023, der $59.55B betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Pfizer Inc. von 2000 bis 2026
Umsatz am Ende jedes Jahres
| Jahr | Umsatz | ändert |
|---|---|---|
| 2026 (TTM) | $63.70B | 1.78% |
| 2025 | $62.58B | -1.65% |
| 2024 | $63.63B | 6.84% |
| 2023 | $59.55B | -40.64% |
| 2022 | $100.33B | 23.43% |
| 2021 | $81.29B | 95.16% |
| 2020 | $41.65B | 1.16% |
| 2019 | $41.17B | -23.25% |
| 2018 | $53.65B | 2.10% |
| 2017 | $52.55B | -0.53% |
| 2016 | $52.82B | 8.13% |
| 2015 | $48.85B | -1.52% |
| 2014 | $49.61B | -3.84% |
| 2013 | $51.58B | -5.62% |
| 2012 | $54.66B | -10.45% |
| 2011 | $61.04B | -8.98% |
| 2010 | $67.06B | 34.09% |
| 2009 | $50.01B | 3.55% |
| 2008 | $48.30B | -0.27% |
| 2007 | $48.43B | 0.12% |
| 2006 | $48.37B | 2.04% |
| 2005 | $47.41B | -9.73% |
| 2004 | $52.52B | 16.22% |
| 2003 | $45.19B | 39.59% |
| 2002 | $32.37B | 0.35% |
| 2001 | $32.26B | 9.08% |
| 2000 | $29.57B | 0.00% |
Umsatz vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Umsatz | Umsatzunterschied | Land |
|---|---|---|---|
| $79.67B | 25.07% |
US
|
|
| $99.34B | 55.95% |
US
|
|
| $64.39B | 1.08% |
US
|
|
| $66.40B | 4.25% |
US
|
|
| $77.52B | 21.70% |
CH
|
